SV Health Investors Research
Investment Thesis
SV Health Investors is a specialist healthcare venture capital and growth equity firm whose stated mission is "empowering innovators to improve patients' lives." Founded three decades ago, the firm has built a reputation as one of the longest-running dedicated healthcare investors in the US and Europe, with a stated goal to "transform healthcare one investment at a time." The firm organizes itself around three distinct, specialist-staffed strategies rather than a single generalist fund: Therapeutics (precision-medicine biotech), Healthcare Growth (services and digital health), and Medtech (medical devices and remote-monitoring technology). Each strategy is run by a dedicated investment team with its own dedicated funds, reflecting a "company creation" and operational-support model rather than passive capital deployment.
Stage Focus
SV's stage focus varies meaningfully by strategy. The Therapeutics team invests from seed capital through early clinical development, frequently creating companies in-house around novel science (e.g., CRISPR, bicyclic peptides, PARP inhibition, immuno-oncology, NK-cell engineering, and AI-supported drug discovery). The Healthcare Growth strategy is explicitly growth-stage, targeting companies with a minimum of roughly $5M in revenue that are near or at break-even. The Medtech strategy (via the $90M Medtech Convergence Fund) focuses on early-stage and seed medical device and technology companies. Overall, SV spans seed through growth/buyout, making it a full-lifecycle healthcare investor rather than a single-stage shop.
Check Size
Exact check sizes were not disclosed publicly for any of the three strategies. Fund sizes give an approximate signal of typical deployment scale: the Medtech Convergence Fund is $90M, the Dementia Discovery Fund family has raised over $550M across two funds (DDF-2 alone closed at $269M in May 2025), and the Growth Fund and Biotech funds are larger, multi-hundred-million-dollar vehicles. Given SV's public $4B AUM figure and long track record (SEC Form ADV discretionary AUM was reported near $1.05B as of March 2025, likely reflecting only a subset of vehicles), check sizes are best understood as ranging from single-digit-million seed checks in Therapeutics/Medtech up to much larger growth and buyout checks in Healthcare Growth.
Lead Tendency
SV Health Investors leads or co-leads the large majority of its investments. The Growth Fund explicitly states it "serves as lead or co-lead, assumes a board seat and customizes investments" for portfolio companies. The Therapeutics strategy's company-creation approach — originating and building companies internally around scientific platforms — implies an even deeper lead/founding role in many deals. Overall lead tendency is assessed as "leads."
Recent Activity
SV has remained active through 2025 and into 2026:
- July 2026: Portfolio company Alchemab Therapeutics secured what was described as the British Business Bank's largest-ever life sciences investment, backing its AI-enabled antibody discovery pipeline.
- April 2026: SV Health Investors acquired EpiVax, Inc., a Providence, RI-based bioanalytical CRO specializing in immunogenicity risk assessment, as a new platform investment in outsourced pharma services.
- March 2026: Portfolio company Perfuze received FDA clearance for Millipede88, the first super-bore aspiration catheter cleared for standalone direct aspiration.
- February 2026: Portfolio company Pivot Point Consulting was folded into a unified healthcare IT company following its acquisition by Innovative Consulting Group.
- January 2026: Three SV-created biotech companies were named to The Times 100 Tech Ones to Watch list, and Miles Gerson (formerly Head of Takeda Ventures) joined as Partner to co-lead the Dementia Discovery Funds and expand US investment activity.
- May 2025: The Dementia Discovery Fund closed DDF-2 at $269M, backed by LPs including Biogen, BMS, Eli Lilly, GSK, J&J, Pfizer and Takeda, alongside the Alzheimer's Association and Alzheimer's Research UK.
Fund status is assessed as actively deploying given the DDF-2 close, the new EpiVax platform investment, and continued portfolio follow-on activity in 2026.
Portfolio Highlights
SV's active portfolio spans roughly 86 companies across its three strategies, including Adimab, Xilio Therapeutics, Bicycle Therapeutics, Artios Pharma, Nimbus Therapeutics, Cerevance, Quell Therapeutics, Prilenia, QurAlis, and Alchemab Therapeutics in Therapeutics; Endotronix, Perfuze, and SpectraWAVE in Medtech; and Evidation Health, AdaptHealth, Podimetrics, and Schweiger Dermatology in Healthcare Growth. SV also has an extensive exit history of roughly 140 M&A, IPO, and recapitalization events, including marquee names like Insulet, American Well, Ocular Therapeutix, and Shire Pharmaceuticals — reflecting the firm's three-decade track record.
Team
SV Health Investors is led by a large partnership spanning offices in Boston and London, organized by strategy:
- Kate Bingham, Managing Partner (Therapeutics, UK)
- Tom Flynn, Managing Partner (Healthcare Growth, USA)
- Michael Balmuth, Managing Partner (Healthcare Growth, USA)
- Paul LaViolette, Managing Partner (Medtech, USA)
- Greg Madden, Managing Partner (Medtech/Healthcare Growth, USA)
- Nikola Trbovic, Managing Partner (Therapeutics, USA)
- Mike Ross, Senior Partner (Therapeutics, USA)
- Laurence Barker, Partner (Therapeutics, UK)
- Jamil M. Beg, Partner (Therapeutics, USA)
- Miles Gerson, Partner (Therapeutics, USA) — joined January 2026 from Head of Takeda Ventures
- Christian Jung, Partner (Therapeutics, UK)
- A.J. Rossi, Partner (Healthcare Growth, USA)
- James Costine, Chief Financial Officer & Partner (UK)
- Brent Faduski, Chief Financial Officer, Chief Compliance Officer & Partner (USA)
- Eugene Hill, Chairman (Healthcare Growth, USA)
The firm also maintains a bench of Venture Partners, Operating Partners, and Executives in Residence who support portfolio companies operationally, plus a dedicated Scientific Advisory Board for the Dementia Discovery Fund and a Growth Fund Advisory Board of healthcare executives.
Decision Process
SV operates as a multi-partner partnership rather than a solo-GP structure, with each of the three strategies (Therapeutics, Healthcare Growth, Medtech) run by its own team of Managing Partners and Partners. Decisions appear to be made at the strategy level with dedicated investment teams, consistent with a "partnership" decision process rather than a single generalist investment committee spanning all three verticals.
Founder Preferences
SV's Therapeutics team frequently originates and co-founds companies around novel scientific platforms rather than purely backing pre-formed founding teams, suggesting a strong preference for deep scientific/technical talent it can pair with in-house company-building expertise. In Healthcare Growth and Medtech, SV backs experienced management teams at revenue-generating, growth-stage companies (minimum ~$5M revenue, approaching break-even), indicating a preference for proven operators over first-time founders at that stage.
Geographic Focus
SV Health Investors is dual-headquartered in Boston, MA (28 State Street, Financial District) and London, UK (71 Kingsway, WC2B 6ST), and invests across the US, UK, and Europe. The Dementia Discovery Fund specifically targets a portfolio "primarily across the US, UK and Europe." SV Health Managers is authorized and regulated in the UK by the Financial Conduct Authority (registration number 409119).